<DOC>
	<DOCNO>NCT00553787</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety VI0521 compare placebo treatment obesity adult population obesity relate co-morbid condition .</brief_summary>
	<brief_title>Study VI-0521 Compared Placebo Treatment Diabetes Obesity Adults With Obesity-Related Co-Morbid Conditions</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<criteria>Informed Consent BMI ≥ 27 ( low BMI limit Type 2 diabetic ) 70 year age less Have 2 follow obesityrelated comorbid condition : Systolic blood pressure 140160 mmHg ( 130160 diabetic ) ; Diastolic blood pressure 90100 mmHg ( 85100 diabetic ) ; Requirement 2 medication achieve control ( &lt; 140/90 mmHg ) Triglyceride level 200400 mg/dL requirement 2 medication achieve control ( &lt; 200 mg/dL ) At lease one follow metabolic criterion : Fasting blood glucose level &gt; 100 mg/dL Glucose level &gt; 140 mg/dL Diagnosis type 2 diabetes Waist circumference ≥ 102 cm men ≥88 cm woman Stroke/MI/unstable cardiovascular disease within 6 month Clinically significant renal , hepatic psychiatric disease Unstable thyroid disease replacement therapy Nephrolithiasis Obesity know genetic endocrine origin Participation formal weight loss program lifestyle intervention Glaucoma intraocular pressure Pregnancy breastfeed Drug Alcohol abuse Smoking cessation within previous 3 month plan quit smoke study Eating disorder Cholelithiasis within past 6 month Excluded medication Type 1 diabetes use antidiabetic medication metformin Previous bariatric surgery Bipolar disorder psychosis Steroid hormone therapy Systolic blood pressure &gt; 160 mmHg , diastolic blood pressure &gt; 100 mmHg Creatinine clearance &lt; 60 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Obesity , Type 2 diabetes</keyword>
</DOC>